Georges Gemayel - Sep 13, 2024 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: Director
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Stock symbol: SUPN
Transactions as of: Sep 13, 2024
Transactions value $: -$320,448
Form type: 4
Date filed: 9/17/2024, 04:10 PM
Previous filing: Jun 14, 2024
Next filing: Nov 8, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SUPN	Common Stock	Sale	-$122K	-3.89K	-22.59%	$31.33	13.3K	Sep 13, 2024	Direct	F1
transaction	SUPN	Common Stock	Options Exercise	$115K	+10K	+75.1%	$11.46	23.3K	Sep 13, 2024	Direct
transaction	SUPN	Common Stock	Sale	-$313K	-10K	-42.89%	$31.33	13.3K	Sep 13, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Director Stock Option (Right to Buy)	Options Exercise	$0	-10K	-28.57%	$0.00	25K	Sep 13, 2024	Common Stock	10K	$11.46	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.12 to $31.50. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.12 to $31.50. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.